Trials / Completed
CompletedNCT00092924
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRAIL-R1 mAb (TRM-1;HGS-ETR1) |
Timeline
- Primary completion
- 2005-01-01
- Completion
- 2005-03-01
- First posted
- 2004-09-28
- Last updated
- 2013-08-02
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00092924. Inclusion in this directory is not an endorsement.